CLBT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellebrite DI Ltd (CLBT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown solid financial performance and positive analyst ratings, the technical indicators are bearish, and there are no significant positive catalysts or trading signals to suggest an immediate entry point. Holding off for a better entry point or more favorable signals is recommended.
The technical indicators for CLBT are bearish. The MACD is negatively expanding, the RSI is neutral at 33.914, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is currently trading near its key support level (S1: 13.865), with resistance at R1: 14.843. The stock has a high probability of declining further in the short term based on historical candlestick patterns.
Strong financial performance in Q4 2025, with revenue up 18.13% YoY and net income up 7.68% YoY.
Positive analyst sentiment with multiple Buy ratings and confidence in ARR re-acceleration.
High gross margin of 84.71%, indicating operational efficiency.
Bearish technical indicators, including a negatively expanding MACD and bearish moving averages.
Recent price decline (-2.61% in regular market and -1.84% in pre-market).
Lack of recent news or significant positive events to drive short-term momentum.
No recent congress trading data or influential figure activity.
In Q4 2025, Cellebrite reported strong financial results, with revenue increasing by 18.13% YoY to $128.82M, net income rising by 7.68% YoY to $20.75M, and EPS remaining stable at 0.08. Gross margin improved slightly to 84.71%, showcasing operational efficiency.
Analysts maintain a Buy rating on CLBT despite lowering price targets due to market contraction. Price targets now range from $18 to $23, reflecting confidence in the company's ARR growth (21% YoY) and solid 2026 guidance.
